Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATAHC II recent hepatitis C study
ACTRN12611000513910Phase 4Completed
- Sponsor
- University of New South Wales
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 arms), sponsored by University of New South Wales. Primary endpoint: Sustained virological response at 24 weeks after therapy. Started Sep 2011; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12611000513910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000513910.